OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.100
-0.005 (-0.45%)
Nov 18, 2026, 4:00 PM EST - Market closed
OKYO Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Urcosimod’s phase II results showed substantial pain reduction and potential corneal nerve improvement, supporting the ongoing NEPTUNE phase III trial. Enrollment is targeted for mid-2027, with top-line data expected in H2 2027; early market research signals premium pricing potential.